When you learn something new, when you fix a memory, when you leave an exercise session with a clearer head, BDNF is involved. It is what researchers call a neurotrophic factor: a protein that literally nourishes neurons, strengthens the connections between them, and stimulates the formation of new synapses.
There is a molecule that science investigates precisely for its capacity to modulate this system. It was synthesized in a laboratory in the 1980s. It is composed of just seven amino acids. And its name is Semax.
BDNF is to the brain what fertilizer is to plants. Semax is investigated for triggering the system that produces it.
What BDNF is, and why neuroscience became obsessed with it
BDNF is not a new concept. Researchers have studied its role in brain biology for decades. But it was in the past two decades that its centrality in the field of cognition and neuroplasticity became clear enough to place it at the center of dozens of simultaneous lines of research.
Synaptic plasticity is the process by which the brain literally reorganizes itself in response to experience. Each time you learn something, connections between neurons are strengthened or created. BDNF is one of the principal mediators of this process, acting as a chemical signal that tells neurons: “grow, connect, survive.”
What makes BDNF so interesting from a research standpoint is not only what it does, but what happens when it diminishes. Aging models, neurodegenerative-disease models, even depression models: in many of these contexts, researchers document reductions in BDNF levels. This turns any molecule capable of modulating this system into an object of immediate scientific interest.
What is the TrkB receptor? BDNF does not act alone. To have an effect, it needs to bind to its receptor: TrkB (Tropomyosin Receptor Kinase B). When that fit happens, it triggers intracellular signaling cascades, the MAPK/ERK and PI3K/Akt pathways, associated with neuronal survival, synaptic plasticity, and memory consolidation. Semax, according to the studies, not only raises BDNF: it also increases the expression of TrkB itself, potentiating the system’s receptivity.
What studies investigate in Semax
In 2006, researchers published in the journal Brain Research a study that would become a reference in the literature on Semax. The group of the scientist Dolotov and colleagues administered the heptapeptide in Wistar rats and measured what happened in the hippocampus, the brain region most associated with memory formation.
The results were notable for a single compound of seven amino acids: a 1.4-fold increase in BDNF protein levels, a 3-fold increase in BDNF mRNA (the genetic signal that encodes its production), a 2-fold increase in TrkB receptor mRNA, and a 1.6-fold increase in TrkB phosphorylation, that is, in the actual activation of the receptor. The treated animals also showed an increase in the number of conditioned-avoidance reactions in behavioral tests.
What this means, in direct language: Semax appears to speak the language of the hippocampus. It not only stimulates the production of BDNF, it tunes the entire system to receive that signal more efficiently.
A single dose produced a 3-fold increase in BDNF mRNA in the hippocampus. For a heptapeptide, that is a notable pharmacological signature.
Beyond memory: BDNF as a link between systems
One of the reasons the BDNF/TrkB axis is so studied is that it does not operate in isolation. BDNF is a known potentiator of dopamine release, which may explain, at least partially, why studies identified that Semax potentiates dopaminergic responses in animal models. It also dialogues with the serotonergic system: research in rodents documented elevations in serotonin metabolites in the striatum after administration of the compound.
This is not trivial. It means a molecule that acts on BDNF is, indirectly, touching systems that neuroscience associates with motivation, mood, attention. Not as side effects, but as part of an interconnected biological network that BDNF helps orchestrate.
If the mechanisms observed in animal models are confirmed in high-quality human studies, the conversation about Semax may cease to be a footnote in Western neuroscience and come to occupy a much larger space. For now, what exists is a promising direction, and a molecule with a pharmacological signature that continues to draw attention.
And human studies? Most clinical data on Semax come from Russia, where the compound has regulatory approval for neurological indications. A Russian clinical trial in 110 stroke patients (Polunin et al., 2018) reported elevation in plasma BDNF levels in patients treated with Semax. A pilot study with 24 healthy volunteers (Lebedeva et al., 2018) identified changes in the resting-state fMRI signal in the default mode network. These data are exploratory, with small samples and methodological limitations, but they represent a body of evidence that no other synthetic nootropic molecule has managed to accumulate so far.
Why this matters for research on brain aging
One of the most active frontiers of contemporary neuroscience is the biology of brain aging. As neurons age, synaptic plasticity diminishes. The formation of new memories becomes slower. The brain’s capacity to reorganize in response to challenges is reduced. And BDNF is one of the most studied biological markers in this decline process.
This places any molecule investigated for modulating the BDNF/TrkB axis in a position of direct interest for researchers studying cognitive longevity. Semax, in this context, is a molecule science is still learning to read, but whose initial signals point to a direction that would be very much worth understanding better.
The question researchers ask is not “does this compound work?”, that is the wrong question for the current phase of the science. The right question is: “which mechanisms does it trigger, in which contexts, with what magnitudes?” And it is exactly that question that the literature on Semax is slowly beginning to answer.
